Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$35.91
Change (%) Stock is Down 1.86 (4.92%)
Volume911,505
Data as of 11/14/18 4:00 p.m. ET
Refresh quote
Featured Events
Webcast ImageWebcast
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting (Live)
12/03/18 at 3:00 p.m. ET
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting
Monday, December 3, 2018 3:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Presentation
Download Documentation Corporate Presentation (November 2018)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
11/06/18GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the third quarter ended September 30, 2018. “Voxelotor has the potential to be a transformative treatment for the sickle cell community. We remain in active discussions with the U.S. Food and Drug Administration regarding the potential for accelerated approval of voxelotor. We continue to believe that voxelotor meets th... 
Printer Friendly Version
11/06/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 1, 2018, the compensation committee of the Company’s board of directors granted seven new employees options to purchase an aggregate of 23,750 shares of the Company’s common stock with a per share exercise price of $39.41, the closing trading price on the grant date, and restricted stock units for an aggregate of 15,700 shares of th... 
Printer Friendly Version
11/01/18GBT Announces Upcoming Data Presentations at 60th American Society of Hematology (ASH) Annual Meeting & Exposition
Company to Present Three Oral Presentations, Including Results Beyond 12 Weeks from Part A of the HOPE Study Company to Host Investor Webcast on Monday, December 3 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD) development programs, including voxelotor, have been accepted for oral and poster presentation during the 60th American Society of Hematolog... 
Printer Friendly Version
10/04/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on October 1, 2018, the compensation committee of the Company’s board of directors granted 10 new employees options to purchase an aggregate of 63,250 shares of the Company’s common stock with a per share exercise price of $36.90, the closing trading price on the grant date, and restricted stock units for an aggregate of 42,800 shares of the Company’s common ... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
12/03/18 3:00 p.m. ET
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.